BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 38110408)

  • 1. Cdo1-Camkk2-AMPK axis confers the protective effects of exercise against NAFLD in mice.
    Chen M; Zhu JY; Mu WJ; Luo HY; Li Y; Li S; Yan LJ; Li RY; Guo L
    Nat Commun; 2023 Dec; 14(1):8391. PubMed ID: 38110408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tetrahydropalmatine ameliorates hepatic steatosis in nonalcoholic fatty liver disease by switching lipid metabolism via AMPK-SREBP-1c-Sirt1 signaling axis.
    Yin X; Liu Z; Wang J
    Phytomedicine; 2023 Oct; 119():155005. PubMed ID: 37562090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic Klf10-Fh1 axis promotes exercise-mediated amelioration of NASH in mice.
    Luo HY; Mu WJ; Chen M; Zhu JY; Li Y; Li S; Yan LJ; Li RY; Yin MT; Li X; Chen HM; Guo L
    Metabolism; 2024 Jun; 155():155916. PubMed ID: 38615945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phytochemical gallic acid alleviates nonalcoholic fatty liver disease via AMPK-ACC-PPARa axis through dual regulation of lipid metabolism and mitochondrial function.
    Zhang J; Zhang W; Yang L; Zhao W; Liu Z; Wang E; Wang J
    Phytomedicine; 2023 Jan; 109():154589. PubMed ID: 36610145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Betulinic acid alleviates non-alcoholic fatty liver by inhibiting SREBP1 activity via the AMPK-mTOR-SREBP signaling pathway.
    Quan HY; Kim DY; Kim SJ; Jo HK; Kim GW; Chung SH
    Biochem Pharmacol; 2013 May; 85(9):1330-40. PubMed ID: 23435355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Downregulation of hepatic ceruloplasmin ameliorates NAFLD via SCO1-AMPK-LKB1 complex.
    Xie L; Yuan Y; Xu S; Lu S; Gu J; Wang Y; Wang Y; Zhang X; Chen S; Li J; Lu J; Sun H; Hu R; Piao H; Wang W; Wang C; Wang J; Li N; White MF; Han L; Jia W; Miao J; Liu J
    Cell Rep; 2022 Oct; 41(3):111498. PubMed ID: 36261001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protopanaxadiol ameliorates NAFLD by regulating hepatocyte lipid metabolism through AMPK/SIRT1 signaling pathway.
    Li Y; Liu Y; Chen Z; Tang K; Yang L; Jiang Y; Wang J; Huang P; Wang J; Zheng P; Song H
    Biomed Pharmacother; 2023 Apr; 160():114319. PubMed ID: 36724639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reducing VEGFB accelerates NAFLD and insulin resistance in mice via inhibiting AMPK signaling pathway.
    Li R; Li Y; Yang X; Hu Y; Yu H; Li Y
    J Transl Med; 2022 Jul; 20(1):341. PubMed ID: 35907871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypericin attenuates nonalcoholic fatty liver disease and abnormal lipid metabolism via the PKA-mediated AMPK signaling pathway in vitro and in vivo.
    Liang C; Li Y; Bai M; Huang Y; Yang H; Liu L; Wang S; Yu C; Song Z; Bao Y; Yi J; Sun L; Li Y
    Pharmacol Res; 2020 Mar; 153():104657. PubMed ID: 31982488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salvia-Nelumbinis naturalis improves lipid metabolism of NAFLD by regulating the SIRT1/AMPK signaling pathway.
    Liu Y; Li Y; Wang J; Yang L; Yu X; Huang P; Song H; Zheng P
    BMC Complement Med Ther; 2022 Aug; 22(1):213. PubMed ID: 35945571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Berberine attenuates nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1 pathway.
    Zhu X; Bian H; Wang L; Sun X; Xu X; Yan H; Xia M; Chang X; Lu Y; Li Y; Xia P; Li X; Gao X
    Free Radic Biol Med; 2019 Sep; 141():192-204. PubMed ID: 31226399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fisetin Protects Against Hepatic Steatosis Through Regulation of the Sirt1/AMPK and Fatty Acid β-Oxidation Signaling Pathway in High-Fat Diet-Induced Obese Mice.
    Liou CJ; Wei CH; Chen YL; Cheng CY; Wang CL; Huang WC
    Cell Physiol Biochem; 2018; 49(5):1870-1884. PubMed ID: 30235452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atractylenolide III ameliorates Non-Alcoholic Fatty Liver Disease by activating Hepatic Adiponectin Receptor 1-Mediated AMPK Pathway.
    Li Q; Tan JX; He Y; Bai F; Li SW; Hou YW; Ji LS; Gao YT; Zhang X; Zhou ZH; Yu Z; Fang M; Gao YQ; Li M
    Int J Biol Sci; 2022; 18(4):1594-1611. PubMed ID: 35280674
    [No Abstract]   [Full Text] [Related]  

  • 14. Maternal exercise conveys protection against NAFLD in the offspring via hepatic metabolic programming.
    Bae-Gartz I; Kasper P; Großmann N; Breuer S; Janoschek R; Kretschmer T; Appel S; Schmitz L; Vohlen C; Quaas A; Schweiger MR; Grimm C; Fischer A; Ferrari N; Graf C; Frese CK; Lang S; Demir M; Schramm C; Fink G; Goeser T; Dötsch J; Hucklenbruch-Rother E
    Sci Rep; 2020 Sep; 10(1):15424. PubMed ID: 32963289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deletion of hepatocyte cysteine dioxygenase type 1, a bile acid repressed gene, enhances glutathione synthesis and ameliorates acetaminophen hepatotoxicity.
    Chen J; Matye D; Dai Clayton Y; Du Y; Nazmul Hasan M; Gu L; Li T
    Biochem Pharmacol; 2024 Apr; 222():116103. PubMed ID: 38428825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resveratrol protects against nonalcoholic fatty liver disease by improving lipid metabolism and redox homeostasis via the PPARα pathway.
    Huang Y; Lang H; Chen K; Zhang Y; Gao Y; Ran L; Yi L; Mi M; Zhang Q
    Appl Physiol Nutr Metab; 2020 Mar; 45(3):227-239. PubMed ID: 31173696
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiotrophin-1 eliminates hepatic steatosis in obese mice by mechanisms involving AMPK activation.
    Castaño D; Larequi E; Belza I; Astudillo AM; Martínez-Ansó E; Balsinde J; Argemi J; Aragon T; Moreno-Aliaga MJ; Muntane J; Prieto J; Bustos M
    J Hepatol; 2014 May; 60(5):1017-25. PubMed ID: 24362075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic regulator of G protein signaling 14 ameliorates NAFLD through activating cAMP-AMPK signaling by targeting Giα1/3.
    Wang J; Guo Y; He Y; Qin Y; Li X; Yang L; Liu K; Xiao L
    Mol Metab; 2024 Feb; 80():101882. PubMed ID: 38237897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Demethyleneberberine attenuates non-alcoholic fatty liver disease with activation of AMPK and inhibition of oxidative stress.
    Qiang X; Xu L; Zhang M; Zhang P; Wang Y; Wang Y; Zhao Z; Chen H; Liu X; Zhang Y
    Biochem Biophys Res Commun; 2016 Apr; 472(4):603-9. PubMed ID: 26970305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LB100 ameliorates nonalcoholic fatty liver disease
    Chen XY; Cai CZ; Yu ML; Feng ZM; Zhang YW; Liu PH; Zeng H; Yu CH
    World J Gastroenterol; 2019 Dec; 25(45):6607-6618. PubMed ID: 31832001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.